Patients with stage IIIB/IV nonsquamous NSCLC were randomly assigned to @-week cycles of carboplatin ( area under the curve @ ) and paclitaxel ( @ mg/m ( @ ) ) with daily placebo ( arm A ) , linifanib @ mg ( arm B ) , or linifanib @ mg ( arm C ) .